In the middle of winter 2021, with COVID-19 stresses running high, music teacher Lisa Bianconi started noticing stomach pains. At first, she suspected a stomach ulcer. But she kept getting sick.
By the spring, as she shopped for wedding dresses with her daughter, Bianconi knew something was wrong. Tests revealed a mass the size of a peach hidden in her abdomen. It was not an ulcer, but stage four diffuse large B-cell lymphoma, a type of aggressive non-Hodgkin lymphoma.
Bianconi immediately started a standard regimen of treatment, first chemotherapy and then radiation, at Dartmouth Cancer Center. She stayed upbeat during the months-long process, getting out to ski in the afternoons following treatment sessions, and seeing both her daughter and son get married.
Despite her optimism, the standard treatments failed. She was given six months to live.
But Bianconi was offered one final option: a relatively new immunotherapy treatment called chimeric antigen receptor (CAR) T-cell therapy.
“At that point, CAR T-cell therapy was considered the last resort,” says Bianconi, who was the 13th patient at Dartmouth Cancer Center to receive CAR T-cell therapy. “When you know this is your last chance, you begin to prepare for war. You are fighting for your life.”
While many standard treatments, such as chemotherapy and radiation, blast cancer cells with toxic chemicals to kill them, CAR T-cell therapy takes a different approach. As a type of immunotherapy, it coaxes a patient’s own immune system into fighting cancer.
A newcomer to the field of cancer treatments, CAR T-cell therapy is just beginning to prove its potential, in part thanks to Dartmouth’s own trailblazing researchers.
“Cell therapy is transforming how we treat cancer. These drugs have long-lasting benefits and let people go back to being people and not just cancer patients,” says Konstantin Dragnev, MD, interim director of Dartmouth Cancer Center. “At Dartmouth Cancer Center, we are building upon a history of discovery and innovation to lead that charge.”
Dartmouth discoveries have been laying the groundwork for immunotherapy since the 1970s, and today new investments in Dartmouth Cancer Center’s research and clinical infrastructure are cementing that legacy, as the Cancer Center launches a center for cell therapy to bridge critical gaps between cutting-edge research and life-saving clinical care. With an influx of new initiatives, Dartmouth researchers are making incredible progress to develop CAR T-cell therapies and other cell therapies, for curing not only cancer but a range of other diseases as well.

